Incyte Corp. (INCY)
128.87
+3.86
(+3.09%)
USD |
NASDAQ |
Sep 02, 16:00
128.84
-0.03
(-0.02%)
After-Hours: 19:31
Incyte Research and Development Expense (TTM) : 2.098B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.098B |
| March 31, 2026 | 2.079B |
| December 31, 2025 | 2.000B |
| September 30, 2025 | 1.871B |
| June 30, 2025 | 1.954B |
| March 31, 2025 | 2.615B |
| December 31, 2024 | 2.607B |
| September 30, 2024 | 2.585B |
| June 30, 2024 | 2.388B |
| March 31, 2024 | 1.650B |
| December 31, 2023 | 1.628B |
| September 30, 2023 | 1.684B |
| June 30, 2023 | 1.693B |
| March 31, 2023 | 1.639B |
| December 31, 2022 | 1.586B |
| September 30, 2022 | 1.557B |
| June 30, 2022 | 1.508B |
| March 31, 2022 | 1.505B |
| December 31, 2021 | 1.458B |
| September 30, 2021 | 1.391B |
| June 30, 2021 | 1.494B |
| March 31, 2021 | 1.438B |
| December 31, 2020 | 2.216B |
| September 30, 2020 | 2.123B |
| June 30, 2020 | 1.966B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.969B |
| December 31, 2019 | 1.154B |
| September 30, 2019 | 1.145B |
| June 30, 2019 | 1.157B |
| March 31, 2019 | 1.165B |
| December 31, 2018 | 1.198B |
| September 30, 2018 | 1.341B |
| June 30, 2018 | 1.318B |
| March 31, 2018 | 1.221B |
| December 31, 2017 | 1.326B |
| September 30, 2017 | 1.041B |
| June 30, 2017 | 914.53M |
| March 31, 2017 | 833.01M |
| December 31, 2016 | 581.86M |
| September 30, 2016 | 536.91M |
| June 30, 2016 | 525.80M |
| March 31, 2016 | 517.97M |
| December 31, 2015 | 479.51M |
| September 30, 2015 | 461.60M |
| June 30, 2015 | 418.06M |
| March 31, 2015 | 390.30M |
| December 31, 2014 | 347.52M |
| September 30, 2014 | 323.82M |
| June 30, 2014 | 306.99M |
| March 31, 2014 | 283.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | 282.06M |
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Eli Lilly & Co. | 14.60B |
| AbbVie, Inc. | 9.714B |
| Biogen, Inc. | 1.736B |